Search





Search





Markets
/
Stocks
/
nasdaq-fbrx
/

Forte Biosciences Inc

FBRX

Add to Watchlist

23.110USD

-0.850-3.55%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

473.27MMarket Cap

LossP/E TTM



Forte Biosciences Inc

23.110

-0.850-3.55%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Forte Biosciences Inc

Currency: USD Updated: 2026-05-15

Key Insights

Forte Biosciences Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 110 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 63.75.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Forte Biosciences Inc's Score

Industry at a Glance

Industry Ranking

110 / 382

Overall Ranking

236 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Forte Biosciences Inc Highlights

StrengthsRisks

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -5.04, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 12.72M shares, increasing 2.22% quarter-over-quarter.

Held by Steven Cohen

Star Investor Steven Cohen holds 792.98K shares of this stock.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

63.750

Target Price

+166.07%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of Forte Biosciences Inc is 6.67, ranking 214 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.67

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.97

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.62

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Forte Biosciences Inc's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of Forte Biosciences Inc is 6.36, ranking 278 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -5.04, which is -94.92% below the recent high of -0.26 and -8583.66% above the recent low of -438.05.

Score

Industry at a Glance

Previous score

6.36

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 110/382

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

The current earnings forecast score of Forte Biosciences Inc is 8.33, ranking 134 out of 382 in the Biotechnology & Medical Research industry. The average price target is 61.00, with a high of 75.00 and a low of 19.00.

Score

Industry at a Glance

Previous score

8.40

Change

-0.07

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

63.750

Target Price

+166.07%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Forte Biosciences Inc

FBRX

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Ionis Pharmaceuticals Inc

IONS

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of Forte Biosciences Inc is 6.74, ranking 166 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 31.42 and the support level at 18.20, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.58

Change

0.16

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.957

Sell

RSI(14)

37.957

Neutral

STOCH(KDJ)(9,3,3)

17.370

Oversold

ATR(14)

2.112

High Vlolatility

CCI(14)

-143.902

Sell

Williams %R

82.860

Oversold

TRIX(12,20)

-0.676

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

24.404

Sell

MA10

25.453

Sell

MA20

27.200

Sell

MA50

27.550

Sell

MA100

28.502

Sell

MA200

21.419

Buy

Institutional Confidence

Currency: USD Updated: 2026-05-15

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Federated Hermes Global Investment Management Corp.

1.77M

+7.96%

Fred Alger Management, LLC

1.46M

-10.70%

Janus Henderson Investors

1.43M

+1.56%

OrbiMed Advisors, LLC

1.20M

Affinity Asset Advisors LLC

812.56K

-17.88%

Point72 Asset Management, L.P.

Star Investors

792.98K

+62.74%

Tybourne Capital Management (HK) Limited

786.65K

Cable Car Capital LLC

400.00K

-20.00%

Adage Capital Management, L.P.

333.33K

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Forte Biosciences Inc is 2.12, ranking 240 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 2.97. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.